While Dyne Therapeutics Inc has overperformed by 0.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN rose by 105.98%, with highs and lows ranging from $47.45 to $11.66, whereas the simple moving average fell by -20.04% in the last 200 days.
On December 13, 2024, Robert W. Baird started tracking Dyne Therapeutics Inc (NASDAQ: DYN) recommending Outperform. A report published by RBC Capital Mkts on November 26, 2024, Initiated its previous ‘Outperform’ rating for DYN. JP Morgan also Downgraded DYN shares as ‘Neutral’, setting a target price of $35 on the company’s shares in a report dated October 24, 2024. Chardan Capital Markets Reiterated the rating as Buy on May 21, 2024, but set its price target from $31 to $42. Morgan Stanley initiated its ‘Overweight’ rating for DYN, as published in its report on April 30, 2024. H.C. Wainwright’s report from February 20, 2024 suggests a price prediction of $36 for DYN shares, giving the stock a ‘Buy’ rating. Raymond James also rated the stock as ‘Strong Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Dyne Therapeutics Inc (DYN)
One of the most important indicators of Dyne Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -68.69% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 17.02, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and DYN is recording 1.01M average volume. On a monthly basis, the volatility of the stock is set at 5.65%, whereas on a weekly basis, it is put at 5.70%, with a loss of -7.66% over the past seven days. Furthermore, long-term investors anticipate a median target price of $50.42, showing growth from the present price of $26.16, which can serve as yet another indication of whether DYN is worth investing in or should be passed over.
How Do You Analyze Dyne Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 23.60%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 86.84% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
DYN shares are owned by institutional investors to the tune of 86.84% at present.
